Cymbalta and Breast cancer metastatic - a phase IV clinical study of FDA data

Summary:

Breast cancer metastatic is found among people who take Cymbalta, especially for people who are 50-59 old, have been taking the drug for 2 - 5 years.

The phase IV clinical study analyzes which people take Cymbalta and have Breast cancer metastatic. It is created by eHealthMe based on reports of 135,967 people who have side effects when taking Cymbalta from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 07, 2023

135,967 people reported to have side effects when taking Cymbalta.
Among them, 64 people (0.05%) have Breast cancer metastatic.

What is Cymbalta?

Cymbalta has active ingredients of duloxetine hydrochloride. It is often used in depression. eHealthMe is studying from 145,347 Cymbalta users for its effectiveness, alternative drugs and more.

What is Breast cancer metastatic?

Breast cancer metastatic is found to be associated with 946 drugs and 461 conditions by eHealthMe.

Number of Cymbalta and Breast cancer metastatic reports submitted per year:

Could Cymbalta cause Breast cancer metastatic?

Time on Cymbalta when people have Breast cancer metastatic *:

Age of people who have Breast cancer metastatic when taking Cymbalta *:

Common drugs people take besides Cymbalta *:

Common side effects people have besides Breast cancer metastatic *:

Nausea (feeling of having an urge to vomit): 31 people, 48.44%
Nosebleed (bleeding from nose): 30 people, 46.88%
Pain: 30 people, 46.88%
Anhedonia (inability to experience pleasure from activities usually found enjoyable): 28 people, 43.75%
Joint Pain: 28 people, 43.75%
Neuropathy Peripheral (surface nerve damage): 27 people, 42.19%
Diarrhea: 26 people, 40.62%
Injury: 24 people, 37.50%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 24 people, 37.50%
Osteonecrosis Of Jaw (death of bone of jaw): 24 people, 37.50%

Common conditions people have *:

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 12 people, 18.75%
Multiple Myeloma (cancer of the plasma cells): 6 people, 9.38%
Pain: 6 people, 9.38%
Breast Cancer: 6 people, 9.38%
Metastases To Bone (cancer spreads to bone): 5 people, 7.81%
Insomnia (sleeplessness): 4 people, 6.25%
Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection): 4 people, 6.25%
Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 4 people, 6.25%
Neuropathy Peripheral (surface nerve damage): 4 people, 6.25%
Breast Cancer Stage Ii: 3 people, 4.69%

* Approximation only. Some reports may have incomplete information.

Do you take Cymbalta and have Breast cancer metastatic?

Check whether Breast cancer metastatic is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Breast cancer metastatic and when was it recovered:

Breast cancer metastatic in Cymbalta

Expand to all the drugs that have ingredients of duloxetine hydrochloride:

Breast cancer metastatic and drugs with ingredients of duloxetine hydrochloride

Alternative drugs to, pros and cons of Cymbalta:

Cymbalta (145,347 reports)

Common Cymbalta side effects:

Fatigue (feeling of tiredness): 13,883 reports
Dizziness: 13,318 reports
Headache (pain in head): 11,606 reports
Pain: 11,210 reports
Stress and anxiety: 10,457 reports
Drug ineffective: 10,368 reports
Insomnia (sleeplessness): 9,690 reports

Browse all side effects of Cymbalta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Breast cancer metastatic treatments and more:

Breast cancer metastatic (74,068 reports)

COVID vaccines that are related to Breast cancer metastatic:

Common drugs associated with Breast cancer metastatic:

Prempro: 3,297 reports
Premarin: 3,253 reports
Provera: 2,473 reports
Letrozole: 1,324 reports
Medroxyprogesterone acetate: 878 reports
Zometa: 796 reports
Capecitabine: 628 reports
Exemestane: 610 reports
Xeloda: 599 reports
Faslodex: 517 reports

How the study uses the data?

The study uses data from the FDA. It is based on duloxetine hydrochloride (the active ingredients of Cymbalta) and Cymbalta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.